Authors
Khaja Mohiddin Shaik, Komala Pandurangan, Srinu Bhoomandla, Kishore Mendam, Punna Reddy Ullapu
Published in
Chemistry & biodiversity. Volume 23. Issue 8. Pages e71539.
Abstract
We report the synthesis and assessment of novel benzimidazole-triazole scaffolds (4a-4j) as antimicrobial/antitubercular medicines. Two-pot condensation processes were used to synthesize the target compounds. Spectroscopic techniques such as mass spectrometry and nuclear magnetic resonance (1H/13C) spectroscopy were used to characterize the synthesized molecules. The remarkable in vitro activity of compounds 4d and 4h (MICs 2.65 ± 1.10 and 2.57 ± 0.34 µM) is comparable activity to conventional drug Streptomycin (MIC = 2.90 ± 0.47 µM), indicates that these are promising new class of anti-tubercular medicines. Among the tested molecules, 4h and 4i exhibited exceptional antibacterial activity with minimum inhibitory concentrations of 3.15 ± 0.23 and 4.81 ± 0.18 µM against the Bacillus cereus, when compared to Moxifloxacin (MIC = 3.52±0.60 µM). Antifungal profiles showed that compounds 4d and 4i had better antifungal inhibitory potency against Fusarium oxysporum with MIC values of 4.91 ± 1.51 and 3.68 ± 0.12 µM, respectively. Solid binding affinities (-6.85 to -9.26 kcal/mol) with the Mycobacterium TB DprE1 (PDB code: 4FDN) and methicillin-resistant Staphylococcus aureus (PDB ID: 1MWR) through important active sites of H-bond and hydrophobic interaction residues are shown by the in silico molecular docking studies, which offer solid support for their mode of action.
PMID:
42538581
Bibliographic data and abstract were imported from PubMed on 01 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0